{"id":401598,"date":"2020-12-17T07:03:19","date_gmt":"2020-12-17T12:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401598"},"modified":"2020-12-17T07:03:19","modified_gmt":"2020-12-17T12:03:19","slug":"c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","title":{"rendered":"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WATERTOWN, Mass., Dec.  17, 2020  (GLOBE NEWSWIRE) &#8212; C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000<sup>\u00ae<\/sup> and Russell 3000<sup>\u00ae<\/sup> Indexes as part of the Russell quarterly update, effective December 21, 2020.<\/p>\n<p>The Russell 2000<sup>\u00ae<\/sup> Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000<sup>\u00ae<\/sup> provides automatic inclusion in the appropriate growth and value style indexes. The Russell 2000<sup>\u00ae<\/sup> Index is a constituent part of the Russell 3000<sup>\u00ae<\/sup> Index, which measures the performance of the 3,000 largest publicly traded U.S. companies based on market capitalization.<\/p>\n<p>\u201cWe are pleased to be added to the Russell Indexes only two months after our IPO,\u201d said Andrew Hirsch, President and Chief Executive Officer at C4 Therapeutics. \u201cC4T\u2019s inclusion will broaden our exposure to the investment community, as we prepare to enter the clinic with our lead candidate, CFT7455 for hematologic malignancies, and advance our mission to discover and develop medicines that destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.\u201d<\/p>\n<p>The Russell U.S. Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes. Russell U.S. Indexes are part of FTSE Russell, a leading global index provider.<\/p>\n<p>For more information about the Russell<sup>\u00ae<\/sup> U.S. Indexes and the Russell Indexes reconstitution, visit the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7Uw2nP9W9sMXi5RQiXHPbGaZnNtGYAwUyDIwsDLnyn_DioLWuXargNvFin2a9P9pVa6XHbT3LKjbAEa6jbjfxDvVaXF5DSinXMuH47YP_w929ssit4Z_J60_YenvIFjT6My8CVGlHOA26Wz1xMd2vUZIoZ3-nWiRfzroN1wkKXY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">FTSE Russell<\/a> website.<\/p>\n<p>\n        <strong>About C4 Therapeutics<\/strong><br \/>\n        <br \/>C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body\u2019s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hE71oNz56OFKQUz4D6wkDulJ4lfbXyVg0t4oA50L9uF-PwOIg_wdeXMDMJaZ4wouj0A-raoUAgrfHXmI1XOIGiaIhVvpMIN5_Mg-NHs6UO0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.C4Therapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO\u2122 platform in the development of novel, selective, orally bioavailable degraders; the potential timing and advancement of our preclinical studies and clinical trials; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our current resources and cash runway; and regulatory developments in the United States and foreign countries. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing and conduct of studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will not be successfully developed and commercialized; and the risk that the results of preclinical studies and clinical trials will be predictive of future results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause C4T\u2019s actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in C4 Therapeutics\u2019 Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4T undertakes no duty to update this information unless required by law.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e685910b-8774-4826-a2c4-cd6b1baa35cf\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor &amp; Media Contact:\r\nKendra Adams\r\nSVP, Communications &amp; Investor Relations\r\nKendra.Adams@c4therapeutics.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes as part of the Russell quarterly update, effective December 21, 2020. The Russell 2000\u00ae Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000\u00ae provides automatic inclusion in the appropriate growth and value style indexes. The Russell 2000\u00ae Index is a constituent part of the Russell 3000\u00ae Index, which measures the performance of the 3,000 largest publicly traded U.S. companies based on market capitalization. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401598","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes as part of the Russell quarterly update, effective December 21, 2020. The Russell 2000\u00ae Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000\u00ae provides automatic inclusion in the appropriate growth and value style indexes. The Russell 2000\u00ae Index is a constituent part of the Russell 3000\u00ae Index, which measures the performance of the 3,000 largest publicly traded U.S. companies based on market capitalization. &hellip; Continue reading &quot;C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T12:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes\",\"datePublished\":\"2020-12-17T12:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"},\"wordCount\":694,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\",\"name\":\"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=\",\"datePublished\":\"2020-12-17T12:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","og_locale":"en_US","og_type":"article","og_title":"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","og_description":"WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes as part of the Russell quarterly update, effective December 21, 2020. The Russell 2000\u00ae Index measures the performance of the small cap segment of the U.S. equity market. Membership in the Russell 2000\u00ae provides automatic inclusion in the appropriate growth and value style indexes. The Russell 2000\u00ae Index is a constituent part of the Russell 3000\u00ae Index, which measures the performance of the 3,000 largest publicly traded U.S. companies based on market capitalization. &hellip; Continue reading \"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T12:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes","datePublished":"2020-12-17T12:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"},"wordCount":694,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","name":"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=","datePublished":"2020-12-17T12:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzQ1MCMzODg0ODQ5IzIyMDAzODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"C4 Therapeutics to be Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401598"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}